Beatrice McQueen Email

Chief Operating Officer . Simcha Therapeutics

Current Roles

Employees:
15
Revenue:
$2.3M
About
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simcha's lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020. A Phase 1 trial is expected to be launched in the first half of 2021. Simcha was founded by Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine. The company has received $25 million in funding to date and is based in New Haven, Conn.
Simcha Therapeutics Address
New Haven, Connecticut , US
New Haven, CT
United States
Simcha Therapeutics Email

Past Companies

Simcha TherapeuticsChief Operating Officer
Beatrice Perotti, Inc.President

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.